Molecular Partners and Orano Med have dosed the first patients in a U.S. multicenter Phase I/II study of MP0712, a lead-212 (Pb-212)-targeted alpha therapy candidate for small cell lung cancer (SCLC) and other neuroendocrine tumors.
MP0712 is a designed ankyrin repeat protein (DARPin) that targets delta-like ligand 3 (DLL3), a protein expressed in more than 85% of SCLC tumors and in multiple other aggressive neuroendocrine cancers, according to the companies. The program uses a theranostic approach: patients first undergo a SPECT/CT imaging and dosimetry step with a lead-203 (Pb-203)-labeled MP0712 before receiving up to four doses of the Pb-212-labeled therapeutic.
The study is ongoing across five currently active U.S. sites, with additional sites planned. Initial data are expected later in 2026, with a broader safety and efficacy dataset anticipated in 2027, the companies noted.
For similar updates and the latest in radiopharmaceutical activity, check out AuntMinnie's Radiopharmaceutical (RPT) Tracker.
